Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Upgraded by StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research note on Monday, September 9th.

Oramed Pharmaceuticals Stock Up 0.4 %

Shares of Oramed Pharmaceuticals stock opened at $2.37 on Friday. Oramed Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $3.67. The firm has a market cap of $95.54 million, a PE ratio of 21.55 and a beta of 1.70. The business has a 50-day moving average price of $2.37 and a 200 day moving average price of $2.40.

Institutional Trading of Oramed Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in Oramed Pharmaceuticals in the 2nd quarter valued at about $40,000. Dimensional Fund Advisors LP increased its stake in Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Oramed Pharmaceuticals during the third quarter worth about $272,000. Renaissance Technologies LLC lifted its position in shares of Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares in the last quarter. Finally, Murchinson Ltd. boosted its stake in shares of Oramed Pharmaceuticals by 0.5% in the third quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after purchasing an additional 8,889 shares during the period. 12.73% of the stock is owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.